Nine eyes with parafoveal choroidal neovascular membranes due to age-related macular degeneration or angioid streaks were treated with a diode laser and were followed up. to 40 weeks (mean 26 weeks). Angiographically proved closure of the membrane was achieved in seven eyes. Four lesions needed a second treatment for growth of subretinal neovascular tissue. Post-treatment visual acuity ranged from 6/9 to 6/60. Two eyes developed subfoveal membranes resulting in poor visual acuity. The morphology of the diode laser lesions differed from that of the argon green laser and was more similar to that of the krypton laser, producing a 'black hole' on the fluorescein positive print. In one particular eye fluorescein angiography revealed subfoveal choroidal non-perfusion next to the site of the diode lesion suggesting choroidal vascular closure. (BrJ Ophthalmol 1993; 77: 218-221) 
The use of argon laser photocoagulation to treat subretinal neovascular membranes was first described in the early 1970s.1'-Subsequent trials have demonstrated that this form of treatment may reduce the incidence of severe visual loss. -7 It was an early observation that macular irradiation with blue-green light (488 nm) resulted in damage to the nerve fibre layer owing to absorption within the xanthophyll pigment. This has led to the deployment of longer wavelengths of laser radiation for the treatment of macular conditions -for example, argon green (514 nm) or krypton red (647 nm). "I Within this spectral wave band absorption within macular luteal pigment is very low.
Recent advances in semiconductor technology have resulted in the development of the diode laser. This has a number of advantages over current laser systems. These favourable 
Results
Of the nine neovascular membranes treated, three were no longer detectable by fluoregcein angiography 1 week after photocoagulation, and remained so for the follow-up period. Four others were not detectable at 1 week, but new vessels again became visible 1 month after therapy. These four eyes underwent diode laser photocoagulation a second time. Subsequent fluorescein angiography has demonstrated no signs of neovascularisation. In two eyes the membrane initially was not detectable in the fluorescein angiogram, but at 3 months there was subfoveal extension, resulting in a visual acuity of 6/60.
A change of two lines on the Snellen chart was taken to denote a significant decrease or increase in visual acuity. Accordingly, visual acuity had improved in one patient, was unchanged in four patients, and had deteriorated in four patients after a mean review period of6 months (Table 1) .
During therapy it was noted that no patient perceived any sensation ofbright flashes. Mild areas, and photocoagulation scars were clearly seen following subsequent resorption of the blood. There was excellent penetration through retinal oedema and serous thickening. Acute diode laser lesions appeared deeper and more greyish when compared with argon lesions but coagulation of the underlying neovascular complex was intense. In all postoperative fluorescein angiograms the site of coagulation appeared completely dark with well defined atrophy of the choriocapillaris. The margins of the laser scars were not hyperfluorescent (Fig 2) .
One particular patient who was treated twice for neovascular tissue contiguous to the former treatment scar showed subfoveal choroidal closure abjacent to the site of treatment (Fig 3) .
Only the very late phase of the angiogram revealed moderate choroidal filling in this particular area. It was assumed that a feeder vessel of a subfoveal choroidal lobe had been occluded by the recurrent diode laser coagulation. The visual acuity in this eye was not affected.
Discussion
A non-destructive mode of treatment for exudative macular degeneration or a preventive therapy are not available as yet, and the natural course of the disease has very poor visual outcome as shown by Bressler.'9 Therefore, early detection of new vessel complexes and photocoagulation remain the only means to reduce the risk of major visual loss.
Photocoagulation should be carried out using the best available laser source.20 Despite the limited period ofreview, this pilot study suggests that diode laser photocoagulation is effective at inducing angiographic closure of choroidal neovascular membranes. The clinical appearance of the diode lesions was similar to that seen in relation to krypton red exposures, the burn being greyer and less white than argon induced lesions.'0I8 Photocoagulation with near infrared has a number of biophysical advantages over treatment with laser radiation of shorter wavelengths. There is better transmission through media opacities -for example, nuclear sclerotic cataracts, and through blood. In relation to macular irradiation, while absorption of radiation of wavelength 488 nm (argon blue-green) within luteal pigment is of the order of 70%, it is less than 1% with krypton red or diode near infrared.2" Thus, while irradiation with the latter two wavelengths will give a burn which is confined to the outer retina, and choroid, treatment with argon blue-green will result in a second locus of laser absorption within the inner retina, with damage to the nerve fibre layer and consequently central scotomatous field defects.9
The potential for non-therapeutic damage by blue-green light is not confined to the patient. Recent clinical studies22 have demonstrated the development of tritanopic defects in colour vision in surgeons using argon blue-green lasers. These defects are usually temporary, but in more frequent and longstanding laser users, the changes may become permanent. These changes are related to photochemical effects induced in blue sensitive cones by relatively high energy short wavelength light. They have not been observed in relation to green or red light. It may be expected therefore that diode near infrared irradiation in the macular region would demonstrate a similar level of safety.
Absorption of energy at 810 nm is very low within haemoglobin. It is clear therefore that closure of neovascular membranes must be achieved by absorption within melanin of the retinal pigment epithelium or within the choroidal melanocytes. Although absorption within melanin ofdiode near infrared radiation is only 15% of that seen in association with argon blue-green, it may be seen from the present study that sufficient power was available to effect anatomical closure of the membrane. The most notable treatment induced incident was the closure of a choroidal lobe extending from the site of coagulation (Fig 3) In conclusion, the diode laser therapy appears as effective as other laser sources in coagulating subretinal neovascular tissue. It combines the favourable wavelength characteristics of the krypton red laser, in relation to its high transmission through blood, oedema, and macular xanthophyll, with the advantages of portable, less bulky, and less costly equipment. Clearly the long term effectiveness of diode laser photocoagulation in the treatment of subretinal neovascular membranes needs to be established when compared with argon green therapy. Clinical trials to examine this are currently in progress.
